IP Library Granted Patent US 11,135,414
Granted Patent B2
US 11,135,414 · App. 16/040,773 · Granted Oct 5, 2021

Medical devices for delivery of siRNA

Inventor: Russell Frederick Ross (Atlanta, GA)
Assignee: SORRENTO THERAPEUTICS, INC.
A61M37/0015A61M5/158A61M37/00C12N15/113C12N15/89A61M2037/0023A61M2037/0038A61M2037/0053A61M2037/0061C12N2310/14Y10T29/49826
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,135,414
App. No.
16/040,773
Granted
Oct 5, 2021
Kind
B2
Abstract

Disclosed are medical devices that incorporate siRNA. In addition to one or more siRNA constructs, devices include nanostructures fabricated on a surface to form a nanotopography. A random or non-random pattern of structures may be fabricated such as a complex pattern including structures of differing sizes and/or shapes. Microneedles may be incorporated on devices. The pattern including nanostructures may be formed on the surface of the microneedles.

Claims (22)

1. A device for delivery of an siRNA construct across a dermal barrier, the device comprising:

a microneedle and a plurality of nanostructures located on a surface of the microneedle to project outward from the surface of the microneedle, the nanostructures being arranged in a pattern that comprises a fractal and/or fractal-like geometry; and

an siRNA construct in fluid communication with the microneedle.

2. The device of claim 1 , wherein the surface of the microneedle further includes microstructures, wherein the nanostructures have a cross-sectional dimension smaller than the microstructures.

3. The device of claim 2 , further comprising second nanostructures having a cross-sectional dimension less than the cross-sectional dimension of the microstructures and greater than the cross-sectional dimension of the first nanostructures.

4. The device of claim 1 , wherein at least a portion of the nanostructures have a cross-sectional dimension of less than about 500 nanometers and greater than about 5 nanometers.

5. The device of claim 1 , wherein at least a portion of the nanostructures have a center-to-center spacing of from about 50 nanometers to about 1 micrometer.

6. The device of claim 1 , wherein at least a portion of the nanostructures have a height of from about 10 nanometers to about 20 micrometers.

7. The device of claim 1 , wherein at least a portion of the nanostructures have an aspect ratio of from about 0.15 to about 30.

8. The device of claim 1 , wherein the siRNA agent includes a duplexed region of between about 20 and about 30 pairs.

9. The device of claim 1 , at least one strand of the siRNA including a 3′ overhang of two or three nucleotides.

10. The device of claim 1 , the siRNA agent comprising additional nucleotides or nucleotide analogue.

11. The device of claim 1 , wherein the siRNA agent comprises a nucleotide sequence that is identical to a portion of a targeted gene.

12. The device of claim 1 , wherein the siRNA agent includes insertions, deletions, or single point mutations compared to a portion of a targeted gene.

13. The device of claim 1 , wherein the siRNA agent is a single strand siRNA.

14. The device of any of claim 1 , wherein the siRNA comprises a ligand tethered to the siRNA.

15. The device of claim 1 , wherein the siRNA agent is incorporated into a delivery vehicle.

16. The device of claim 1 , wherein the siRNA construct comprises a vector.

17. The device of claim 1 , wherein the nanostructures are fabricated on a film, and wherein the film is laid over the microneedle.

18. A method for delivering an siRNA construct across a dermal barrier, the method comprising:

penetrating the stratum corneum with a microneedle having a surface on which a plurality of nanostructures are arranged in a pattern that comprises a fractal and/or fractal-like geometry, wherein the nanostructures project outward from the surface of the microneedle, and wherein the microneedle further contains a channel;

transporting an siRNA construct from a reservoir through the channel of the microneedle and across the stratum corneum.

Assignments (6)
TERMINATION AND RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Sep 21, 2023
From: SCILEX HOLDING COMPANY
To: SORRENTO THERAPEUTICS, INC.; SCINTILLA PHARMACEUTICALS, INC.
Reel/Frame 065017/0844 →
RELEASE OF SECURITY INTEREST Recorded Aug 11, 2023
From: JMB CAPITAL PARTNERS LENDING, LLC
To: SORRENTO THERAPEUTICS, INC.; SCINTILLA PHARMACEUTICALS, INC.
Reel/Frame 064571/0848 →
SECURITY INTEREST Recorded Jul 31, 2023
From: SORRENTO THERAPEUTICS, INC.; SCINTILLA PHARMACEUTICALS, INC.
To: SCILEX HOLDING COMPANY
Reel/Frame 064441/0575 →
SECURITY INTEREST Recorded Apr 6, 2023
From: SORRENTO THERAPEUTICS, INC.; SCINTILLA PHARMACEUTICALS, INC.
To: JMB CAPITAL PARTNERS LENDING, LLC
Reel/Frame 063283/0063 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2019
From: ROSS, RUSSELL FREDERICK
To: KIMBERLY-CLARK WORLDWIDE, INC.
Reel/Frame 048152/0780 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2019
From: KIMBERLY-CLARK WORLDWIDE, INC.
To: SORRENTO THERAPEUTICS, INC.
Reel/Frame 048152/0850 →